At Supplement Blueprints, editorial integrity, clinical accuracy, and empirical transparency form the foundation of our publishing mandate. This Editorial Standards & Corrections Policy outlines the rigorous 5-tier verification process every blueprint undergoes before publication.
The 5-Tier Clinical Verification Protocol
- Primary Literature Sourcing: All biochemical assertions, dosage recommendations, and health claims must reference peer-reviewed studies indexed on PubMed, MEDLINE, or established medical journals. Secondary media summaries are never utilized as primary sources.
- Human vs. Non-Human Trial Distinction: Our analysts explicitly differentiate between human clinical trials, observational epidemiology, and animal/in-vitro models. Rodent or cell-culture findings are never presented as definitive human clinical outcomes.
- Pharmacological & Interaction Screening: Protocols identify potential contraindications, cytochrome P450 (CYP) enzyme interactions, and synergistic co-factors to ensure safe application.
- Standardized Extract & Chemical Form Accuracy: We evaluate specific molecular forms (e.g., Magnesium L-Threonate vs. Magnesium Oxide, Hydroxycobalamin vs. Cyanocobalamin) rather than generic compound names.
- No Proprietary Blend Tolerance: We reject and caution against commercial formulations that conceal active component dosages behind proprietary blend labels.
Corrections & Living Protocol Updates
Biomedical science is dynamic. When emerging clinical trials modify the understanding of a compound’s efficacy, safety, or dosage threshold, our editorial team immediately updates the corresponding masterclass. Corrections of factual errors are noted transparently with revision timestamps. To report an error or submit new clinical trial data, contact [email protected].